RxDoctor Payments Data

Douglas Taylor, DPM

Primary Podiatric Medicine · San Leandro, CANPI 1518915693

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.9% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Smith+Nephew at 29.3% of the total.

$3,018in general payments, 2019–2025

Across 36 payments — averaging $83.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$884
  • Bioventus LLC$586
  • Organogenesis Inc.$415
  • Orthofix Medical, Inc.$198
  • Zimmer Biomet$179
  • Kerecis Limited$179
  • plus $576 from 7 others

What the payments were for

  • Speaking & faculty fees$1254%
  • Food & beverage$2,89396%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,018 in reported general payments places this provider in the 80th percentile of 59 primary podiatric medicine providers in California.

See all primary podiatric medicine providers in California

Medicare billing

Part B allowed, 2024
$227,059
Medicare patients
258
Services billed
1,772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tavaborole30$6,648
Ketoconazole60$1,457
CiclopiroxCiclopirox Olamine34$1,080
Allopurinol30$290
Triamcinolone Acetonide13$275
Mupirocin27$271
Cephalexin20$143
Meloxicam21$141
Fluconazole11$108
SsdSilver Sulfadiazine11$59

Paid to pharmacies, not to this prescriber.

Other primary podiatric medicine in San Leandro

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →